The Genentech drug won approval in Europe last week for advanced ovarian cancer. But its maker has no immediate plans to seek the same approval in the United States.
In November, the FDA revoked Avastin's approval for breast cancer. It can still be sold for colon, lung, kidney and brain cancers. The new research was aimed at adding ovarian cancer to the list.